FDA product code · Neurology · Class 2
GXI: Probe, Radiofrequency Lesion
GXI is FDA's product code for "Probe, Radiofrequency Lesion": a Class 2 device classified under 21 CFR 882.4725, reviewed by the Neurology panel.
510(k) review time for GXI
Across 15 510(k) clearances under GXI decided from 2018-01-01 to 2026-10-06, the median was 115 days from FDA receipt to decision. Half took between 91 and 248 days, and 80% were decided within 251 days. These are past clearances, not a forecast for a new submission.
| Fastest | 29 |
|---|---|
| 25th percentile | 91 |
| Median | 115 |
| 75th percentile | 248 |
| 80th percentile | 251 |
| 90th percentile | 255 |
| Slowest | 365 |
Source: openFDA 510(k) records, snapshot of 2026-10-06 (openFDA data as of 2026-09-28). Compare 510(k) review times across all device types, see every code side by side in the Clearance Timeline Estimator, or browse the clearances themselves in PredicateScope.
GXI in the public FDA record
| 510(k) clearances, all years | 66 |
|---|---|
| Device recalls | 29 |
| Establishment listings | 176 |
| GUDID device identifiers | 1,826 |
Counts of records, not of devices or events. Adverse event reports for GXI are in MAUDEScope, as counts with the query shown: MAUDE has no denominator, so a report count is not a rate and does not show that a device caused an event.
FDA-recognized standards that cite GXI
No FDA recognized consensus standard cites GXI by product code. Horizontal standards such as biocompatibility, sterilization and software standards can still apply.
Source: FDA Recognized Consensus Standards, snapshot of 2026-09-01. Search them all in the Consensus Standards Lookup.